Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents May 1, 2017 3 Biotech Stocks That Look Like Apple Did in the 1980s June 21, 2017 Merck & Co. CEO Resigns From American Manufacturing Council by Tweet August 13, 2017
Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents May 1, 2017
